Puma Biotechnology

Biotechnology, Medical, Therapeutics
Founded in 1/1/10
Los Angeles, California, United States
http://www.pumabiotechnology.com
For Profit

About Puma Biotechnology

Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Company Metrics

  • Employees: 251-500
  • Monthly Visits: 562
  • Tech Stack: 11 active products

Financial Information

  • Estimated Revenue: $50M to $100M
  • Total Funding: 809300000 USD
  • Last Funding: 10000000 USD (Post-IPO Equity)
  • Funding Status: IPO

Technology Stack

Puma Biotechnology actively uses 11 products in their tech stack.

Market Presence

Industries: Biotechnology, Medical, Therapeutics

Headquarters: Los Angeles, California, United States

Employees

  • Gordon Esplin - Chief Accounting Officer (LinkedIn)
  • Jeff Ludwig - Chief Commercial Officer (LinkedIn)
  • Maximo Nougues - Chief Financial Officer (LinkedIn)